Advertisement

Imaging and Therapy of Neuroendocrine Tumors of the Abdomen

  • Richard P. Baum
  • Harshad R. Kulkarni

Abstract

THERANOSTICS is an acronym that exemplifies the inseparability of diagnostics and therapeutics in the individualized management of disease. Neuroendocrine tumors (NETs) express somatostatin receptors (SSTRs), enabling the use of somatostatin (SMS) analogs for molecular imaging, when labeled with the positron emitter gallium- 68 (68Ga) for receptor positron emission tomography computed tomography (PET/CT) and targeted radionuclide therapy when labeled with beta-emitters 90Y and 177Lu (Fig. 1). Peptide receptor radionuclide therapy (PRRT) using 90Y- and 177Lu-labeled SMS analogs or a combination of the two (DUO-PRRT) is highly effective in the management of advanced or progressive NETs. Apart from benefit in overall survival from time of diagnosis of several years, significant improvement in clinical symptoms and excellent palliation can be achieved. In patients with progressive NETs, fractionated, personalized PRRT with lower doses of radioactivity given over a longer period of time results in good therapeutic responses.

Keywords

Thymidine Phosphorylase Peptide Receptor Radionuclide Therapy Positron Emission Tomography Compute Tomography SSTR Expression Target Radionuclide Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Rufini V, Baum RP, Castaldi P et al (2012) Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging 37:1004–1020.PubMedCrossRefGoogle Scholar
  3. 3.
    Baum RP, Prasad V (2008) PET and PET/CT imaging of neuroendocrine tumors. In: Wahl R, Beansland RSB (2008) Principles and practice of PET and PET/CT. Lippincott and Williams, Philadelphia, PA.Google Scholar
  4. 4.
    Krenning EP, Kwekkeboom DJ, Bakker WH et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731.PubMedCrossRefGoogle Scholar
  5. 5.
    Decristoforo C, Melendez-Alafort L, Sosabowski JK et al (2000) 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 41:1114–1119.PubMedGoogle Scholar
  6. 6.
    Baum RP, Kulkarni HR, Carreras C (2012) Peptides and receptors in image-guided therapy: THERANOSTICS for neuroendocrine neoplasms. Semin Nucl Med 42:190–207.PubMedCrossRefGoogle Scholar
  7. 7.
    Hofmann M, Maecke H, Borner R et al (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med Mol Imaging 28:1751–1757.CrossRefGoogle Scholar
  8. 8.
    Buchmann I, Henze M, Engelbrecht S et al (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617–1626.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaemmerer D, Peter L, Lupp A et al (2011) Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 8:1659–1668.CrossRefGoogle Scholar
  10. 10.
    Prasad V, Ambrosini V, Hommann M (2010) Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37:67–77.PubMedCrossRefGoogle Scholar
  11. 11.
    Shapiro B, Copp JE, Sisson JC et al (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576–585.PubMedGoogle Scholar
  12. 12.
    Gazdar AF, Helman LJ, Israel MA et al (1988) Expression of neuroendocrine cell markers L-DOPA decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 48:4078–4082.PubMedGoogle Scholar
  13. 13.
    Kolby L, Bernhardt P, Levin-Jakobsen AM et al (2003) Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 89:1383–1388.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Kayani I, Bomanji JB, Groves A et al (2008) Functional imaging of neuroendocrine tumours with combined PET/CT using 240 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112:2447–2455.PubMedCrossRefGoogle Scholar
  15. 15.
    Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46:62S–66S.PubMedGoogle Scholar
  16. 16.
    Bodei L, Cremonesi M, Grana C et al (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90YDOTATOC) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 31:1038–1046.PubMedCrossRefGoogle Scholar
  17. 17.
    Khan S, Krenning EP, van Essen M et al (2011) Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med 52:1361–1368.PubMedCrossRefGoogle Scholar
  18. 18.
    Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130.PubMedCrossRefGoogle Scholar
  19. 19.
    Imhof A, Brunner P, Marincek N et al (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29:2416–2423.PubMedCrossRefGoogle Scholar
  20. 20.
    Anlauf M, Gerlach P, Raffel A et al (2011) Neuroendocrine neoplasia of the gastroenteropancreatic system. Pathology and classification. Onkologe 17:572–582.CrossRefGoogle Scholar
  21. 21.
    Bodei L, Mueller-Brand J, Baum RP et al (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800–816.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Valkema R, Pauwels SA, Kvols LK et al (2005) Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA(0),Tyr(3)-octreotide and 177Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 46:83S–91S.PubMedGoogle Scholar
  23. 23.
    Rolleman EJ, Valkema R, de Jong M et al (2003) Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30:9–15.PubMedCrossRefGoogle Scholar
  24. 24.
    Hörsch D, Bert T, Schrader J et al (2012) Pancreatic neuroendocrine neoplasms. Minerva Gastroenterol Dietol 58:401–426.PubMedGoogle Scholar
  25. 25.
    de Jong M, Breeman WA, Valkema R et al (2005) Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs. J Nucl Med 46:13S–7S.PubMedGoogle Scholar
  26. 26.
    Kunikowska J, Królicki L, Hubalewska-Dydejczyk A et al (2011) Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging 38:1788–1797.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Limouris GS, Chatziioannou A, Kontogeorgakos D et al (2008) Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 35:1827–1837.Google Scholar
  28. 28.
    Claringbold PG, Brayshaw PA, Price RA et al (2011) Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 38:302–311.PubMedCrossRefGoogle Scholar
  29. 29.
    Kaemmerer D, Prasad V, Daffner W et al (2009) Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 15:5867–5870.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  • Richard P. Baum
    • 1
  • Harshad R. Kulkarni
    • 1
  1. 1.THERANOSTICS Center for Molecular Radiotherapy and Molecular ImagingZentralklinik Bad BerkaBad BerkaGermany

Personalised recommendations